Intellia to Report Phase 3 HAELO Data on April 27 – Key Catalyst for in vivo CRISPR

What happened

Intellia Therapeutics will report topline data from its Phase 3 HAELO trial of lonvoguran ziclumeran in hereditary angioedema on April 27, 2026. This is the first Phase 3 readout for an in vivo CRISPR gene editing candidate, making it a pivotal moment for the company and the platform. The data will determine whether the one-time treatment can demonstrate robust efficacy and safety in a competitive HAE prophylaxis market where newer entrants like CSL's Andembry and Ionis' Dawnzera have raised the bar. Given Intellia's pre-revenue status and ongoing losses, the outcome will directly impact its stock price and ability to advance its pipeline, especially while the ATTR program remains under FDA clinical hold. The company will host a webcast at 8 AM ET on April 27 to discuss the results.

Implication

Investors should brace for high volatility around April 27. The data must show a compelling reduction in HAE attacks with a clean safety profile to differentiate from current prophylactics that already offer high efficacy. A positive readout could shift Intellia from a speculative HOLD to a BUY, as it would de-risk platform and pave way for BLA submission in 2H26. Conversely, negative data would severely damage the company’s credibility, given it is the most advanced in vivo CRISPR program, and likely lead to a SELL recommendation as the stock may approach cash value. The clinical hold on the ATTR program (nex‑z) adds further uncertainty, so even a mixed result could be punished by the market.

Thesis delta

The upcoming HAELO data represents the inflection point we flagged as a key watch item. A positive outcome would materially increase our conviction in the platform and likely shift our rating to BUY, as it would validate the in vivo CRISPR approach and support the path to approval. However, the competitive landscape has intensified since our initial analysis, raising the bar for success. Any safety or efficacy concerns in a relatively small Phase 3 trial (single dose) would be detrimental, and we would downgrade to SELL.